

09/838,785

2

51831AUSM1

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, or claims in the application:

**Listing of Claims:**

Claims 1-27 (canceled)

Claim 28 (currently amended) A method for selectively destroying a ~~prostate-derived prostate~~ cell expressing a PROST 03 polypeptide having the amino acid sequence of SEQ ID NO: 2, wherein the method comprises reacting the cell with an immunoconjugate comprising an isolated monoclonal antibody, or antibody fragment thereof, which specifically binds to an epitope present in the PROST 03 polypeptide conjugated to a therapeutic agent ~~with the cell~~, so that the ~~therapeutic agent of the~~ immunoconjugate can destroy the cell.

Claim 29 (previously presented) A method of treating prostate cancer in a human patient, wherein the method comprises administering to the patient a therapeutically effective amount of an immunoconjugate comprising an isolated monoclonal antibody, or antibody fragment thereof, which specifically binds to an epitope present in a PROST 03 polypeptide having the amino acid sequence of SEQ ID NO: 2, conjugated to a therapeutic agent.

Claims 30-38 (canceled)

Claims 39-41 (not entered)

Claim 42 (new) The immunoconjugate of Claim 28 or 29, wherein the therapeutic agent is a cytotoxic agent.

51831AUSM1rcerspnc

09/838,785

3

51831AUSM1

Claim 43 (new) The immunoconjugate of Claim 28 or 29, wherein the cytotoxic agent is selected from the group consisting of ricin, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin D, diphteria toxin, *Pseudomonas* exotoxin (PE) A, PE40, ricin, abrin, glucocorticoid and radioisotopes.

Claim 44 (new) The immunoconjugate of Claim 43, wherein the cytotoxic agent is a radioisotope.

Claim 45 (new) The immunoconjugate of Claim 44, wherein the radioisotope is <sup>90</sup>Y.

51831AUSM1rcerspnc